{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:23:01Z","timestamp":1790616181918,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-53"],"award-info":[{"award-number":["ANR-10-LABX-53"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ligue Nationale contre le Cancer, France"},{"name":"SIRIC Montpellier-Cancer","award":["INCa-DGOS-Inserm 6045"],"award-info":[{"award-number":["INCa-DGOS-Inserm 6045"]}]},{"name":"Inserm-Transfert, France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In ovarian carcinoma, anti-M\u00fcllerian hormone (AMH) type II receptor (AMHRII) and the AMH\/AMHRII signaling pathway are potential therapeutic targets. Here, AMH dose-dependent effect on signaling and proliferation was analyzed in four ovarian cancer cell lines, including sex cord stromal\/granulosa cell tumors and high grade serous adenocarcinomas (COV434-AMHRII, SKOV3-AMHRII, OVCAR8 and KGN). As previously shown, incubation with exogenous AMH at concentrations above the physiological range (12.5\u201325\u00a0nM) decreased cell viability. Conversely, physiological concentrations of endogenous AMH improved cancer cell viability. Partial AMH depletion by siRNAs was sufficient to reduce cell viability in all four cell lines, by 20% (OVCAR8 cells) to 40% (COV434-AMHRII cells). In the presence of AMH concentrations within the physiological range (5 to 15\u00a0pM), the newly developed anti-AMH B10 antibody decreased by 25% (OVCAR8) to 50% (KGN) cell viability at concentrations ranging between 3 and 333\u00a0nM. At 70\u00a0nM, B10 reduced clonogenic survival by 57.5%, 57.1%, 64.7% and 37.5% in COV434-AMHRII, SKOV3-AMHRII, OVCAR8 and KGN cells, respectively. In the four cell lines, B10 reduced AKT phosphorylation, and increased PARP and caspase 3 cleavage. These results were confirmed in ovarian cancer cells isolated from patients\u2019 ascites, demonstrating the translational potential of these results. Furthermore, B10 reduced COV434-MISRII tumor growth in vivo and significantly enhanced the median survival time compared with vehicle (69 <jats:italic>vs<\/jats:italic> 60\u00a0days; p\u2009=\u20090.0173). Our data provide evidence for a novel pro-survival autocrine role of AMH in the context of ovarian cancer, which was targeted therapeutically using an anti-AMH antibody to successfully repress tumor growth.<\/jats:p>","DOI":"10.1038\/s41598-021-81819-y","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T11:05:05Z","timestamp":1611659105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-M\u00fcllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Ma\u00ebva","family":"Chauvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Garambois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Chentouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Brouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jarlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Navarro-Teulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"P\u00e9pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Chard\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"P\u00e8legrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"81819_CR1","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1210\/me.2010-0273","volume":"24","author":"N di Clemente","year":"2010","unstructured":"di Clemente, N. et al. Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta. Mol. Endocrinol. 24, 2193\u20132206 (2010).","journal-title":"Mol. Endocrinol."},{"key":"81819_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0378-3782(93)90204-8","volume":"33","author":"N Josso","year":"1993","unstructured":"Josso, N. et al. Anti-M\u00fcllerian hormone in early human development. Early Hum. Dev. 33, 91\u201399 (1993).","journal-title":"Early Hum. Dev."},{"key":"81819_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.biocel.2011.12.013","volume":"44","author":"D Horbelt","year":"2012","unstructured":"Horbelt, D., Denkis, A. & Knaus, P. A portrait of transforming growth factor \u03b2 superfamily signalling: Background matters. Int. J. Biochem. Cell Biol. 44, 469\u2013474 (2012).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"81819_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.mce.2003.09.022","volume":"211","author":"F Xavier","year":"2003","unstructured":"Xavier, F. & Allard, S. Anti-M\u00fcllerian hormone, beta-catenin and M\u00fcllerian duct regression. Mol. Cell. Endocrinol. 211, 115\u2013121 (2003).","journal-title":"Mol. Cell. Endocrinol."},{"key":"81819_CR5","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1530\/JOE-15-0206","volume":"226","author":"IS McLennan","year":"2015","unstructured":"McLennan, I. S. & Pankhurst, M. W. Anti-M\u00fcllerian hormone is a gonadal cytokine with two circulating forms and cryptic actions. J. Endocrinol. 226, R45-57 (2015).","journal-title":"J. Endocrinol."},{"key":"81819_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1126\/science.472712","volume":"205","author":"PK Donahoe","year":"1979","unstructured":"Donahoe, P. K., Swann, D. A., Hayashi, A. & Sullivan, M. D. M\u00fcllerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. Science 205, 913\u2013915 (1979).","journal-title":"Science"},{"key":"81819_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0046-8177(70)80005-3","volume":"1","author":"RE Scully","year":"1970","unstructured":"Scully, R. E. Recent progress in ovarian cancer. Hum. Pathol. 1, 73\u201398 (1970).","journal-title":"Hum. Pathol."},{"key":"81819_CR8","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/mrd.20858","volume":"75","author":"NA Arango","year":"2008","unstructured":"Arango, N. A. et al. A mesenchymal perspective of M\u00fcllerian duct differentiation and regression in Amhr2-lacZ mice. Mol. Reprod. Dev. 75, 1154\u20131162 (2008).","journal-title":"Mol. Reprod. Dev."},{"key":"81819_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5468\/ogs.2014.57.5.343","volume":"57","author":"JH Kim","year":"2014","unstructured":"Kim, J. H., MacLaughlin, D. T. & Donahoe, P. K. M\u00fcllerian inhibiting substance\/anti-M\u00fcllerian hormone: A novel treatment for gynecologic tumors. Obstet. Gynecol. Sci. 57, 343\u2013357 (2014).","journal-title":"Obstet. Gynecol. Sci."},{"key":"81819_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/labinvest.2011.116","volume":"91","author":"M Anttonen","year":"2011","unstructured":"Anttonen, M. et al. Anti-M\u00fcllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. Lab. Investig. 91, 1605\u20131614 (2011).","journal-title":"Lab. Investig."},{"key":"81819_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mce.2003.09.009","volume":"211","author":"PK Donahoe","year":"2003","unstructured":"Donahoe, P. K., Clarke, T., Teixeira, J., Maheswaran, S. & MacLaughlin, D. T. Enhanced purification and production of M\u00fcllerian inhibiting substance for therapeutic applications. Mol. Cell. Endocrinol. 211, 37\u201342 (2003).","journal-title":"Mol. Cell. Endocrinol."},{"key":"81819_CR12","doi-asserted-by":"publisher","first-page":"e4782","DOI":"10.1002\/bmc.4782","volume":"34","author":"AY Rak","year":"2020","unstructured":"Rak, A. Y. et al. Purification of human recombinant anti-mullerian hormone and its derivatives. Biomed. Chromatogr. 34, e4782 (2020).","journal-title":"Biomed. Chromatogr."},{"key":"81819_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1142\/S2339547813500076","volume":"1","author":"D P\u00e9pin","year":"2013","unstructured":"P\u00e9pin, D. et al. An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian inhibiting substance. Technology 1, 63\u201371 (2013).","journal-title":"Technology"},{"key":"81819_CR14","doi-asserted-by":"publisher","first-page":"E4418","DOI":"10.1073\/pnas.1510604112","volume":"112","author":"D P\u00e9pin","year":"2015","unstructured":"P\u00e9pin, D. et al. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 112, E4418\u2013E4427 (2015).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81819_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2016.06.043","volume":"16","author":"TN Beck","year":"2016","unstructured":"Beck, T. N. et al. Anti-M\u00fcllerian hormone signaling regulates epithelial plasticity and chemoresistance in lung cancer. Cell Rep. 16, 1\u201315 (2016).","journal-title":"Cell Rep."},{"key":"81819_CR16","doi-asserted-by":"publisher","first-page":"a022129","DOI":"10.1101\/cshperspect.a022129","volume":"9","author":"YE Zhang","year":"2017","unstructured":"Zhang, Y. E. Non-smad signaling pathways of the TGF-\u03b2 family. Cold Spring Harb. Perspect. Biol. 9, a022129 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"81819_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1472-6750-7-81","volume":"7","author":"P Philibert","year":"2007","unstructured":"Philibert, P. et al. A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm. BMC Biotechnol. 7, 81 (2007).","journal-title":"BMC Biotechnol."},{"key":"81819_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-61779-974-7_6","volume":"907","author":"G Robin","year":"2012","unstructured":"Robin, G. & Martineau, P. Synthetic customized scFv libraries. Methods Mol. Biol. 907, 109\u2013122 (2012).","journal-title":"Methods Mol. Biol."},{"key":"81819_CR19","first-page":"247","volume":"7","author":"CA Wilson","year":"1993","unstructured":"Wilson, C. A. et al. Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily. Mol. Endocrinol. 7, 247\u2013257 (1993).","journal-title":"Mol. Endocrinol."},{"key":"81819_CR20","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.1073\/pnas.93.15.7711","volume":"93","author":"MW Nachtigal","year":"1996","unstructured":"Nachtigal, M. W. & Ingraham, H. A. Bioactivation of M\u00fcllerian inhibiting substance during gonadal development by a kex2\/subtilisin-like endoprotease. Proc. Natl. Acad. Sci. U.S.A. 93, 7711\u20137716 (1996).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81819_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1210\/jcem-54-5-1051","volume":"54","author":"AF Fuller","year":"1982","unstructured":"Fuller, A. F., Guy, S., Budzik, G. P. & Donahoe, P. K. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line. J. Clin. Endocrinol. Metab. 54, 1051\u20131055 (1982).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"81819_CR22","first-page":"3488","volume":"5","author":"PT Masiakos","year":"1999","unstructured":"Masiakos, P. T. et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin. Cancer Res. 5, 3488\u20133499 (1999).","journal-title":"Clin. Cancer Res."},{"key":"81819_CR23","first-page":"2640","volume":"8","author":"AE Stephen","year":"2002","unstructured":"Stephen, A. E. et al. Highly purified m\u00fcllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin. Cancer Res. 8, 2640\u20132646 (2002).","journal-title":"Clin. Cancer Res."},{"key":"81819_CR24","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1158\/1078-0432.CCR-05-2108","volume":"12","author":"R Pieretti-Vanmarcke","year":"2006","unstructured":"Pieretti-Vanmarcke, R. et al. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin. Cancer Res. 12, 1593\u20131598 (2006).","journal-title":"Clin. Cancer Res."},{"key":"81819_CR25","doi-asserted-by":"publisher","first-page":"15601","DOI":"10.1073\/pnas.2636900100","volume":"100","author":"TU Barbie","year":"2003","unstructured":"Barbie, T. U., Barbie, D. A., MacLaughlin, D. T., Maheswaran, S. & Donahoe, P. K. Mullerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc. Natl. Acad. Sci. U.S.A. 100, 15601\u201315606 (2003).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81819_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1073\/pnas.0407772101","volume":"102","author":"EJ Renaud","year":"2005","unstructured":"Renaud, E. J., MacLaughlin, D. T., Oliva, E., Rueda, B. R. & Donahoe, P. K. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc. Natl. Acad. Sci. U.S.A. 102, 111\u2013116 (2005).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81819_CR27","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1073\/pnas.0409709102","volume":"102","author":"V Gupta","year":"2005","unstructured":"Gupta, V. et al. Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc. Natl. Acad. Sci. U.S.A. 102, 3219\u20133224 (2005).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81819_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mce.2003.09.010","volume":"211","author":"Y Hoshiya","year":"2003","unstructured":"Hoshiya, Y. et al. Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Mol. Cell. Endocrinol. 211, 43\u201349 (2003).","journal-title":"Mol. Cell. Endocrinol."},{"key":"81819_CR29","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1073\/pnas.1120733109","volume":"109","author":"K Meirelles","year":"2012","unstructured":"Meirelles, K. et al. Human ovarian cancer stem\/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc. Natl. Acad. Sci. U.S.A. 109, 2358\u20132363 (2012).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81819_CR30","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1111\/j.1365-2605.2011.01210.x","volume":"34","author":"RP Grinspon","year":"2011","unstructured":"Grinspon, R. P. et al. Early onset of primary hypogonadism revealed by serum anti-M\u00fcllerian hormone determination during infancy and childhood in trisomy 21. Int. J. Androl. 34, e487\u2013e498 (2011).","journal-title":"Int. J. Androl."},{"key":"81819_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/molehr\/gat024","volume":"19","author":"JV Jeppesen","year":"2013","unstructured":"Jeppesen, J. V. et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol. Hum. Reprod. 19, 519\u2013527 (2013).","journal-title":"Mol. Hum. Reprod."},{"key":"81819_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jsbmb.2017.08.011","volume":"174","author":"ZU Rehman","year":"2017","unstructured":"Rehman, Z. U. et al. Role and mechanism of AMH in the regulation of Sertoli cells in mice. J. Steroid Biochem. Mol. Biol. 174, 133\u2013140 (2017).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"81819_CR33","doi-asserted-by":"publisher","first-page":"16421","DOI":"10.1073\/pnas.0508304102","volume":"102","author":"P-Y Wang","year":"2005","unstructured":"Wang, P.-Y. et al. Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc. Natl. Acad. Sci. U.S.A. 102, 16421\u201316425 (2005).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81819_CR34","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1242\/jcs.001230","volume":"120","author":"X Yin","year":"2007","unstructured":"Yin, X. et al. YWK-II protein as a novel G(o)-coupled receptor for M\u00fcllerian inhibiting substance in cell survival. J. Cell. Sci. 120, 1521\u20131528 (2007).","journal-title":"J. Cell. Sci."},{"key":"81819_CR35","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/ijc.29532","volume":"137","author":"A F\u00e4rkkil\u00e4","year":"2015","unstructured":"F\u00e4rkkil\u00e4, A. et al. The clinical utility of serum anti-M\u00fcllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors\u2014A comparative study with inhibin B. Int. J. Cancer 137, 1661\u20131671 (2015).","journal-title":"Int. J. Cancer"},{"key":"81819_CR36","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/ijms20061325","volume":"20","author":"M Gowkielewicz","year":"2019","unstructured":"Gowkielewicz, M. et al. Anti-M\u00fcllerian hormone expression in endometrial cancer tissue. Int. J. Mol. Sci. 20, 1325 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"81819_CR37","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia, J. et al. Bevacizumab (Avastin) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 86, 102017 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"81819_CR38","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone, E. C. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50, 1400\u20131411 (2004).","journal-title":"Arthritis Rheum."},{"key":"81819_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12967-018-1566-8","volume":"16","author":"AJ Pellatt","year":"2018","unstructured":"Pellatt, A. J. et al. The TGF\u03b2-signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs. J. Transl. Med. 16, 191 (2018).","journal-title":"J. Transl. Med."},{"key":"81819_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/0092-8674(86)90783-X","volume":"45","author":"RL Cate","year":"1986","unstructured":"Cate, R. L. et al. Isolation of the bovine and human genes for M\u00fcllerian inhibiting substance and expression of the human gene in animal cells. Cell 45, 685\u2013698 (1986).","journal-title":"Cell"},{"key":"81819_CR41","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/1535-7163.MCT-16-0678","volume":"16","author":"E Chan-Penebre","year":"2017","unstructured":"Chan-Penebre, E. et al. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: In vitro and in vivo preclinical models. Mol. Cancer Ther. 16, 850\u2013860 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"81819_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1210\/endo.142.1.7862","volume":"142","author":"Y Nishi","year":"2001","unstructured":"Nishi, Y. et al. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology 142, 437\u2013445 (2001).","journal-title":"Endocrinology"},{"key":"81819_CR43","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.4161\/mabs.29316","volume":"6","author":"N Kersual","year":"2014","unstructured":"Kersual, N. et al. The human M\u00fcllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4. MAbs 6, 1314\u20131326 (2014).","journal-title":"MAbs"},{"key":"81819_CR44","doi-asserted-by":"publisher","first-page":"e90604","DOI":"10.1371\/journal.pone.0090604","volume":"9","author":"RL O\u2019Donnell","year":"2014","unstructured":"O\u2019Donnell, R. L. et al. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS ONE 9, e90604 (2014).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81819-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81819-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81819-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:27:18Z","timestamp":1670034438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81819-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["81819"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-81819-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]},"assertion":[{"value":"31 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ma\u00ebva Chauvin, Myriam Chentouf, Pierre Martineau, Bruno Robert, and Andr\u00e9 P\u00e8legrin are inventors of a patent \u201cANTI-M\u00dcLLERIAN INHIBITING SUBSTANCE ANTIBODIES AND USES THEREOF\u201d filed on 2019, September, 27. Ma\u00ebva Chauvin, Thierry Chard\u00e8s, Isabelle Navarro-Teulon and Andr\u00e9 P\u00e8legrin are inventors of a patent \u201cUSE OF M\u00dcLLERIAN INHIBITING SUBSTANCE INHIBITORS FOR TREATING CANCER\u201d filed on 2019, September, 27. David P\u00e9pin is inventor of the patent \u201cMODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES\u201d, WO2014164981A1. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2231"}}